GSK to Close UK Antibiotic Factory in Ulverston Following Sandoz Contract Termination

Closure Announcement:
GSK has announced the closure of its antibiotic manufacturing facility in Ulverston, UK, scheduled for June 2025, following the end of its contract with Sandoz.

Background:
In 2021, GSK sold its Cephalosporin antibiotics business to Sandoz, with a four-year manufacturing and supply agreement that would conclude in 2025.

Impact:
Approximately 100 employees are expected to be affected by the closure of the Ulverston site.

Alternative Uses:
GSK is actively seeking alternative uses for the site and is in negotiations with interested stakeholders.

Community Support:
GSK plans to contribute £2 million to the local community to support its development.

Legacy:
The Ulverston facility has a 75-year history of producing medications for nearly two billion patients globally.